BRTX
BioRestorative Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.60
+3.90%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.54
From 52W high−95.15%
Volume18348.00
Market cap$2.21M
P/E (TTM)—
P/S (TTM)6.2x
Div yield—
Key dataOct 19, 2026
Open
$1.54
From 52W high
−95.15%
Volume
18348.00
Market cap
$2.21M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
22.6
MomentumView details →
1D Return
+3.90%
YTD Return
−93.39%
SummaryUpdated Mar 1, 2026
BioRestorative Therapies, Inc. (OTCQB:BRTX) is a life sciences company founded in 1997 and based in Melville, New York, that focuses on developing regenerative medicine products using adult stem cell therapies. Originally incorporated as Stem Cell Assurance, Inc., the company changed its name to BioRestorative Therapies in August 2011 and went public in December 2012. The company operates two primary therapeutic programs: a disc/spine treatment program called brtxDisc and a metabolic disorders program called ThermoStem, both utilizing different types of stem cell technologies to address unmet medical needs.
Similar companies
Latest newsMore news →
BioRestorative Therapies appointed Donald J. Currie as a Class I director, effective October 7, 2026.10d agoMr. Silva resigned as Vice President of Research and Development of BioRestorative Therapies, Inc., effective September 4, 2026.39d agoKatharyn Field resigned as Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Board member of BioRestorative Therapies, effective late August 2026, with successors appointed.48d ago